Study Overview: This clinical trial explores how well the SensoniQ® Treatment Station, which uses low-frequency sound waves, works to help people with nerve problems caused by chemotherapy. These nerve problems, called chemotherapy-induced peripheral neuropathy (CIPN), often occur in patients receiving treatment for gynecologic cancers. Patients in the trial are being treated with two specific chemotherapy drugs, carboplatin and paclitaxel.
What is CIPN? CIPN is a common side effect where patients feel tingling, pain, or weakness in their hands and feet. Currently, there are not many options to prevent or treat this condition. The SensoniQ® Treatment Station aims to reduce these symptoms without causing additional problems.
Participation Details:
- The study involves answering questions and undergoing tests to measure the effectiveness of the treatment.
- Participants must be at least 18 years old and have a gynecologic cancer diagnosis.
- Certain medical conditions or medications may exclude someone from participating.